Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma

Expert Opinion on Biological Therapy
Andreas KatsanosAnastasios G P Konstas

Abstract

Ranibizumab was the first anti-vascular endothelial growth factor (VEGF) agent approved for the treatment of neovascular age-related macular degeneration. The use of ranibizumab and other anti-VEGF medications in recent years has revolutionized the treatment of several sight-threatening retinal disorders. Emerging evidence has demonstrated that anti-VEGF treatment can offer advantages in the management of other ocular conditions where VEGFs play a key role: ocular scarring following glaucoma filtering surgery and neovascular glaucoma (NVG). Areas covered: We critically review available evidence on the use of ranibizumab as a wound healing modulator in glaucoma filtering surgery and as an adjunct in the management of NVG. Expert opinion: Based on the available evidence and the authors' clinical experience, ranibizumab is a valuable adjunct in the management of NVG. In glaucoma filtering surgery, however, the role of ranibizumab is less clear and does not provide a significant advantage over mitomycin C. Drawbacks for its use in glaucoma include cost, its off-label use, uncertainty and limited evidence on the various routes of administration, the optimal dosing schemes and its toxicity profile. Future advances in ranibizumab deli...Continue Reading

References

Sep 23, 2000·Nature·P Carmeliet, R K Jain
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
May 15, 2003·Survey of Ophthalmology·Paul J Lama, Robert D Fechtner
Sep 6, 2003·The Journal of Pharmacy and Pharmacology·Tayade PralhadKale Rajendrakumar
May 26, 2004·Lancet·Robert N Weinreb, Peng Tee Khaw
Jan 27, 2005·Investigative Ophthalmology & Visual Science·Jacques GaudreaultVanessa Shiu
Feb 21, 2006·The British Journal of Ophthalmology·H A Quigley, A T Broman
Aug 11, 2007·Progress in Retinal and Eye Research·Sohan Singh Hayreh
Oct 22, 2008·Progress in Brain Research·Stelios GeorgoulasPeng Tee Khaw
Nov 26, 2008·The Journal of Surgical Research·Philip BaoHarold Brem
Dec 31, 2008·Progress in Retinal and Eye Research·Eduardo B RodriguesCarlos R Zanetti
Jul 4, 2009·Progress in Retinal and Eye Research·Dao-Yi YuXiaobo Yu
Dec 31, 2009·Current Opinion in Ophthalmology·Michael B Horsley, Malik Y Kahook
Mar 2, 2011·MAbs·Charlotte Magdelaine-BeuzelinHervé Watier
May 31, 2011·American Journal of Ophthalmology·Rashmi Mathew, Keith Barton
Sep 13, 2011·Experimental Eye Research·Tine Van BergenIngeborg Stalmans
Jan 18, 2012·Current Opinion in Ophthalmology·Sarwat Salim
Jul 24, 2012·American Journal of Ophthalmology·Tim U KrohneCarsten H Meyer
Sep 12, 2012·Expert Opinion on Biological Therapy·Sung Chul ParkCelso Tello
Oct 17, 2012·Survey of Ophthalmology·Leonard K SeiboldMalik Y Kahook
Jul 31, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Julia LükeSalvatore Grisanti
Jul 16, 2014·Current Eye Research·Michael J ProMarlene R Moster
Aug 19, 2014·Molecular and Cellular Endocrinology·Biff F Palmer, Deborah J Clegg
Dec 22, 2016·Advances in Therapy·Vanessa Andrés-GuerreroAnastasios-Georgios Konstas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.